RNAZ · Annual Report (Form 10-K) · Filed April 15, 2026

Transcode Therapeutics Inc — 10-K exhibit

rnaz-20251231xex23d1.htm

Transcode Therapeutics Inc on Boardroom Alpha

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration Nos. 333-265496 and 333-257868), Registration Statement on Form S-3 (Registration No. 333-292112), and Registration Statements on Form S-1 (Registration Nos. 333-274251, 333-272082 and 333-283668) of Transcode Therapeutics, Inc. (the “Company”) of our report dated April 15, 2026, (which includes an explanatory paragraph relating to Transcode Therapeutics, Inc.’s ability to continue as a going concern), relating to the consolidated financial statements as of and for the years ended December 31, 2025 and 2024, which appear in this Form 10-K.


/s/ WithumSmith+Brown, PC


East Brunswick, New Jersey
April 15, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer